CRSP Stock — CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP)

Updated October 16, 2026.

CRSP is a Stock. Total return is 249.5% over the past 10 years, 67.6 points behind SPY at 317.1%.

CRISPR Therapeutics AG is a gene-editing company developing gene-based medicines using its CRISPR/Cas9 platform, with a portfolio spanning hemoglobinopathies, CAR T cell therapies, in vivo treatments, and type 1 diabetes; its lead product candidate CASGEVY is a gene-edited cell therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease. The company does not currently distribute dividends. This security appeals to growth-oriented investors with interest in biotechnology and gene-therapy innovation.

CRSP performance versus SPY

Price and return data through 2026-10-16.

Total return is 249.5% over the past 10 years, 67.6 points behind SPY at 317.1%. Over the past year its total return — price change plus distributions reinvested — is -28.0%. Its deepest 1-year drawdown was 40.1%.

CRSP key facts

Asset type

Stock

Asset class

Equity

Inception date

10/19/2016

Distribution frequency

None

Last close

$49.25 (as of 2026-10-16)

Market cap

$4,762,113,160

Average volume

1517485.0

Beta

1.759

Payout ratio

0.0%

Forward P/E

23.3645

EPS

$-4.74

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CRSP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 40.1%.

Who may consider CRSP — and who may not

It is a weaker fit for investors who need monthly cash flow (CRSP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CRSP

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions